Matches 1 - 50 out of 136 1 2 3 >

AcclaimIP-ad

Match Document Document Title
US20110293723 SYNTHETIC NANOCARRIER COMBINATION VACCINES  
Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are...
US20150197766 METHODS AND COMPOSITIONS FOR PRODUCTION OF RECOMBINANT PHARMACEUTICAL PROTEINS IN MEDICINAL PLANTS  
Methods of tissue culture and in vitro propagation of medicinal plants, in particular, plants of the genera Hydrastis, Echinacea, Kalanhoe, Thymus and Calendula are described. Methods of...
US20120195928 VACCINES AND METHODS FOR USING THE SAME  
Compositions comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with one or more of CTACK protein, TECK protein, MEC protein and functional fragments...
US20110110979 METHOD AND VACCINE FOR OPTIMIZING THE SPECIFIC IMMUNE RESPONSES  
The present invention relates to a method for treating an infection or disease or lesion, in particular an HPV infection. Furthermore, it relates to a vaccine for treating a Human Papillomavirus...
US20140322268 SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS  
Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L1, L2, L3, L4, L5,...
US20100310602 SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS  
Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L1, L2, L3, L4, L5,...
US20110223195 COMPOSITION COMPRISING CHITOSAN FOR OCULAR ADMINISTRATION OF VACCINE(S) TO AVIANS  
The invention relates to vaccine compositions comprising chitosan and a vaccine which are administered to avian species via the ocular route, and methods or programs of vaccination including use...
US20140141042 Expression Systems  
The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or...
US20110135685 Edible Vaccines Expressed in Soybeans  
The present invention relates to vaccines that are made in transgenic soybeans for use in humans, animals of agricultural importance, pets, and wildlife. These vaccines are used as vaccines...
US20120003277 NANOEMULSION VACCINES  
The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more...
US20110150940 DRY POWDER COMPOSITIONS AND SYSTEMS FOR POULTRY VACCINATION  
This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said...
US20150184198 COMPOSITIONS, METHODS AND USES FOR POXVIRUS ELEMENTS IN VACCINE CONSTRUCTS  
Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing poxvirus constructs. In some embodiments, constructs may contain an influenza...
US20130136767 COMPOSITIONS, METHODS AND USES FOR POXVIRUS ELEMENTS IN VACCINE CONSTRUCTS  
Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing poxvirus constructs. In some embodiments, constructs may contain an influenza...
US20110274649 T-CELL VACCINATION WITH VIRAL VECTORS VIA MECHANICAL EPIDERMAL DISRUPTION  
Attenuated, replication-deficient viruses such as vaccinia viruses are used to deliver an exogenous viral, bacterial, parasitic or tumor antigen to an epidermal tissue such as the skin, lungs or...
US20130230553 MODULATION OF IMMUNE RESPONSES BY THE POXVIRAL K4 PROTEIN  
The present invention relates to compositions, methods, and uses involving the modulation of K4 protein activity, especially in the treatment of various diseases and in the enhancement of...
US20100303894 POX VIRIDAE TREATMENT  
A vaccine composition for combating Pox viridae viral infections in living organisms such as mammals (including humans) comprises TAP-1 and/or TAP-2 to augment the antigen processing capability of...
US20120141465 VIRUS VACCINATION AND TREATMENT METHODS WITH OX40 AGONIST COMPOSITIONS  
The invention relates to compositions and methods that employ OX40 (CD134), a TNFR superfamily protein, agonists. The invention includes among other things administering an OX40 agonist alone or...
US20110212131 METHOD FOR ENHANCING AN IMMUNE RESPONSE  
A vaccine composition for combating Pox viridae viral infections in living organisms such as mammals (including humans) comprises TAP-1 and/or TAP-2 to augment the antigen processing capability of...
US20120189572 VACCINES TARGETING CELLULAR DEATH RECEPTORS  
The invention provides therapeutics and methods to induce a mammalian host, including a human, to produce antibodies, which agonize death receptors and cause the apoptotic death of target cells...
US20150250869 VIRUS-CONTAINING FORMULATION AND USE THEREOF  
The present invention relates to formulation comprising (i) at least one virus-based material, (ii) at least one polymer selected in the group of polyvinylpyrrolidone and derivatives thereof,...
US20130323280 METHODS FOR PREPARING VESICLES AND FORMULATIONS PRODUCED THEREFROM  
The present disclosure provides methods for preparing vesicles. In one aspect, the methods involve providing a molten mixture of vesicle-forming lipids and adding the molten mixture of...
US20110135598 METHODS TO DIAGNOSE AND IMMUNIZE AGAINST THE VIRUS CAUSING HUMAN MERKEL CELL CARCINOMA  
The present invention provides isolated or substantially purified polypeptides, nucleic acids, and virus-like particles (VLPs) derived from a Merkel cell carcinoma virus (MCV), which is a...
US20120201847 Vaccine Formulations and Uses Thereof  
A liquid or liquid-frozen composition comprising: a modified vaccinia Ankara (MVA) virus or variant or derivative thereof and mannitol, wherein mannitol is the sole stabilization agent of the...
US20120328650 MODIFIED VACCINIA ANKARA VIRUS VARIANT  
The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same...
US20110182933 MODIFIED VACCINIA ANKARA VIRUS VARIANT  
The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same...
US20110182932 MODIFIED VACCINIA ANKARA VIRUS VARIANT  
The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same...
US20130209511 Recombinant Poxviral Vectors Expressing both Rabies and OX40 Proteins, and Vaccines Made Therefrom  
The present invention provides vectors that contain and co-express in vivo or in vitro immunogenic polypeptides or antigens together with an OX40L polypeptide, which functions as a genetic...
US20120064151 ENHANCED IMMUNE RESPONSE IN AVIAN SPECIES  
The present invention relates to a method of immune activation which is effective for eliciting a non-antigen-specific immune response in a member of the avian species. The method is particularly...
US20140242115 INACTIVATING PATHOGENS WITH OXIDIZING AGENTS FOR VACCINE PRODUCTION  
The present disclosure provides methods for producing a vaccine composition containing a pathogen that is rendered noninfectious by exposure to hydrogen peroxide. The methods disclosed herein are...
US20150153330 sAPP-alpha as a Biomarker for Prediction of Inflammatory and Autoimmune-Related Disorders  
The subject invention pertains to the use of amyloid precursor protein-alpha (sAPP-α) as a biomarker for prediction of a subject's risk of developing inflammatory and/or autoimmune-related...
US20110287089 USE OF A SACCHAROMYCES CEREVISIAE MITOCHONDRIAL NUCLEIC ACIDS FRACTION FOR IMMUNE STIMULATION  
The present invention relates to the use of a Saccharomyces cerevisiae mitochondrial nucleic acids fraction and an antigen for the preparation of a pharmaceutical composition intended to orient...
US20110081368 Protein vaccines against poxviruses  
The invention described here entails a protein vaccine against poxviruses which contains at least two purified recombinant monkeypox virus proteins or peptides. The proteins or peptides are...
US20130011436 Methods and Compositions Containing Fc Fusion Proteins for Enhancing Immune Responses  
Provided are compositions and methods for inhibiting cell growth. The cells that are targeted by the compositions and methods of the invention express an antigen, a mimotope of the antigen, or a...
US20120045430 DENDRIMER-LIKE MODULAR DELIVERY VECTOR  
Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. The nucleic...
US20110002961 Interleukin 12 paracrine gene delivery enhanced CTL immunotherapy  
A method of treating a patient with a disease wherein the patient contains diseased cells which cells contain antigens for identification and which cells are capable of presenting at least part of...
US20110293658 USE OF INKT OR TLR AGONISTS FOR PROTECTING AGAINST OR TREATING A DISEASE SUCH AS ACUTE INFECTION OR CANCER  
A method of protecting a mammalian subject against, or treating, a disease, wherein the mammalian subject has elevated numbers and/or activities of MDSC comprising administering to the subject a...
US20110064769 VV PROMOTER-DRIVEN OVEREXPRESSION OF RECOMBINANT ANTIGENS  
The present invention is directed to the use of a pharmaceutical composition comprising a vaccinia virus (VV) based vector construct under the control of a strong VV specific promoter. The present...
US20110212123 Immunogenic Substances Comprising a Polyinosinic Acid - Polycytidilic Acid Based Adjuvant  
The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide...
US20110182847 USE OF TLR AGONISTS AND/OR TYPE 1 INTERFERONS TO ALLEVIATE TOXICITY OF TNF-R AGONIST THERAPEUTIC REGIMENS  
Improved (safer and more effective) methods of therapy using TNF-R agonists, e.g., CD40 agonists are provided. These methods provide for the addition of an amount of a type 1 interferon and/or a...
US20140294894 TRANSCUTANEOUS DELIVERY OF THERAPEUTIC AGENTS  
The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to...
US20110142881 TRANSCUTANEOUS DELIVERY OF THERAPEUTIC AGENTS  
The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to...
US20100183672 PROCESS FOR PREPARING LIVE SMALLPOX VACCINE  
A safer live smallpox vaccine, which contains a lowered content of revertants, is provided. A process for manufacturing a live smallpox vaccine which comprises steps of: inoculating a master seed...
US20120039936 INTERGENIC REGIONS AS INSERTION SITES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA (MVA)  
The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further...
US20120276142 NUCLEIC ACID SEQUENCES ENCODING AND COMPOSITIONS COMPRISING IGE SIGNAL PEPTIDE AND/OR IL-15 AND METHODS FOR USING THE SAME  
Fusion proteins and nucleic acid molecules encoding fusion proteins are disclosed. Fusion proteins comprising non-IL-15 signal peptide linked to IL-15 protein sequences and fusion proteins...
US20110300181 PURIFICATION OF VACCINIA VIRUS- AND RECOMBINANT VACCINIA VIRUS-BASED VACCINES  
The present invention relates to methods for purification of Vaccinia viruses (W) and/or Vaccinia virus (W) particles, which can lead to highly pure and stable virus preparations of predominantly...
US20100285099 VACCINATION BY TRANSCUTANEOUS TARGETING  
The present invention relates to a method of vaccination via hair follicles that makes it possible to target vaccine components to the antigen-presenting cells in order to induce a protective and...
US20050053626 Grace process biotechnology patent the cure to the herpes virus  
Step 1. Method of treating disease: this procedure must be done by a certified Medical Doctor, who has access to controlled substances. Doctor is to give patient one normal smallpox vaccination....
US20140044752 INACTIVATED VIRUS COMPOSITIONS AND METHODS OF PREPARING SUCH COMPOSITIONS  
The present invention is directed at a composition comprising a live swine flu virus having an infectious component and a plurality of surface antigens in contact with a formaldehyde donor agent...
US20070298093 Synergistic Liposomal Adjuvants  
The present invention relates to liposome, mixtures or liposomes and liposomal compositions comprising at least two different adjuvants and a therapeutic agent, their production and use for the...
US20090041852 DRY POWDER COMPOSITIONS AND SYSTEMS FOR POULTRY VACCINATION  
This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said...
Matches 1 - 50 out of 136 1 2 3 >